ERDERA Launches the 2025 Joint Transnational Call for Proposals on Rare Disease Therapies

ERDERA Launches the 2025 Joint Transnational Call for Proposals on Rare Disease Therapies

The European Rare Diseases Research Alliance (ERDERA) is delighted to announce the official launch of its 2025 Joint Transnational Call (JTC) for Proposals as of today, 10 December 2024. This eagerly anticipated call invites research teams across Europe and internationally to collaborate on cutting-edge projects aimed at“Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation.”

See all the details of the official call here.

Application Timeline

The JTC 2025 will follow a two-stage submission process:

  • 13 February 2025: Pre-proposal submission deadline.
  • 9 July 2025: Full proposals submission deadline. Funding decisions are expected by December 2025.

Interested applicants can join an informationalwebinar on 17 December 2024, providing valuable guidance on preparing submissions.

For more information, contact the Joint Call Secretariat atSelteneErkrankungen@dlr.de or reach out to the relevant national contact point.

Stay informed with the latest updates from ERDERA by subscribing to our newsletter and following us on social media.

News & Updates

You might also be interested in

July 24 @ 3:00 pm - 4:00 pm
This webinar will present a theoretical framework for situating ethics across research activities. The framework will then be brought to life through a relevant case study discussion, giving participants a concrete reference point for the episodes ahead.
ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.
Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.
The NCL Foundation has opened the Rare-to-Common Neurodegeneration Impact Prize, a €200,000 research award supporting collaborative projects that connect CLN3 Batten disease research with more common neurodegenerative or age-related disorder